Analytical, Life Science & Diagnostics Association (ALDA)’s Post

Exploring Strategic Growth: Cizzle Biotechnology's 2023 Annual Report We are excited to share insights from Cizzle Biotechnology Holdings plc's 2023 Annual Report, which highlights a year of strategic partnerships and advancements in lung cancer detection technologies. Dive into the details of their financial performance, strategic licensing initiatives, and the steps they're taking towards minimizing environmental impact. Discover how these initiatives align with our mission to innovate in healthcare and what lies ahead for Cizzle Biotechnology. 🔗 Read the full summary on our blog: https://buff.ly/4f6vShk #CizzleBiotechnology #AnnualReport #LungCancerAwareness #HealthcareInnovation

Twenty three companies will share from £12 million in funding that has been awarded to advance innovative cancer projects and will be shared by 16 projects led by small and medium-sized enterprises at various stages right from feasibility through to regulatory approval. They include industry-led research and development projects by Antikor Biopharma Ltd, Cell Guidance Systems, Coding Bio, Epitopea, Grey Wolf Therapeutics, Lentitek, Medannex Ltd, Mestag Therapeutics, Momentous Therapeutics Ltd, Pathios Therapeutics, Prokarium, QV Bioelectronics, Revolver Therapeutics, #Sferola, Theolytics, VacV Biotherapeutics Feasibility project by CREASALLIS, Galytx, Kargenera, New Path Molecular Research, #OligoTune, Proteotype Diagnostics & Xgenera Congratulations to you all and we look forward to hearing more about the results Find out more via UK Research and Innovation https://lnkd.in/eg5RsCu8 #CancerResearch #InnovationInHealthcare #SmallBusinessGrants #MedicalInnovation #HealthTech #ClinicalTrials #BiotechFunding #HealthcareInnovation #SMEFunding #ResearchAndDevelopment

Exciting news! Last week, PairX Bio's Co-Founder and President, Dr. David M Epstein, had the pleasure of speaking with Nucleate Singapore about our approach to developing the next generation of cancer-selective biologics through alternative splicing variant targeting. Tune in to hear him talk about the importance of following the science and leaning into transparent conversations about data, the benefits of working in Singapore's biotech ecosystem, and the role of the transcriptome in the future of targeted cancer therapies. Listen today on Spotify or Apple Podcasts. #Biotech #Innovation #Cancer #Podcast

Topics include: Tabloids and Cancer, Momentum in Biotech- Reversion to the Mean, Follow-On Investing and the Q2 2024 Biotech Outlook #theDoctorisIN #wealthmanagement #financialadvisors #pharma

"If someone you know to be thoughtful and rational makes a very different decision than you might under the same circumstance, it’s probably worthwhile to ask what time horizon they are operating under as that might be the root distinction." More than a biotech billionaire, Bob Duggan, CEO of Summit Therapeutics, Inc. has changed and is continuing to change lives. Born out of the death of his son from brain cancer, his dedication to biotech coupled with "intensity to learn and get things right" is admirable. #longtermview #patientcapital #biotech #lifesciences https://lnkd.in/daiV8gUp

At #WorldADC San Diego and want to learn more about our Click Activated Protodrugs Against Cancer platform and how this pre-targeting approach can overcome dose limiting off-target toxicities associated with ADCs?    Look no further than today’s poster session where we’ll be presenting two posters.     Discover how our pre-targeting approach achieves increased tumor-targeted drug exposure while sparing healthy tissues, creating a greater therapeutic index. You can also learn why CEACAM5 is an ideal target for our technology.    Come meet our team, including José M. Mejía Oneto, Travis Biechele, Jesse McFarland, Mukul Agarwal, and Michael Zakharian and explore the future of targeted therapeutics.     #clickchemistry #adc #drugdevelopment #biotech #innovation #research

Lamassu BioTech is ready for Biotechnology Innovation Organization’s #BIO2024 Conference! 🔬 Lamassu CEO Gabi Hanna MD., will be in San Diego throughout #BIO2024, meeting with other leaders in the #biotech industry and exploring opportunities to accelerate hope and healing. Lamassu is transforming the way we treat metastatic cancer and solving the critical unmet medical need of severe acute pancreatitis. SA53, a #noveltherapeutic that targets p53 wild-type sarcomas, has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission that was recently approved by the FDA. This potential best-in-class #precisionmedicines offers new hope for #metastitic #cancertreatment. Companies and investors interested in targeted cancer therapies, or anyone interested in learning about our team’s works, should use the contact form on our website, https://lnkd.in/gnvwYBm, to schedule a meeting during #BIO2024.

Dr. Hon Leong, scientist in the Odette Cancer Research Program at Sunnybrook Research Institute, emphasizes the importance of translating research into clinical practice. Using ideas from his lab, Dr. Leong founded Sunnybrook spin-off company, YEX Inc., a sustainable, ethical and cost-effective alternative to current methods used for growing cells needed to make biologics drugs. His invention has the potential to improve patient outcomes by accelerating the development of life-saving medications and making them more affordable and accessible for patients. Read more about Yex and Dr. Leong’s experience as an inventor in the latest Sunnybrook Inventors blog: https://bit.ly/3Xog69k

We’ve made significant advancements to our OrganoidXplore™ platform 🌟 Expanded Model Library: We now have a total of 64 models in our comprehensive cancer panel, covering 7 indications.  🌐 Enhanced KRAS Mutant Models: We’ve added 7 new KRAS mutant models, bringing the total to 26 KRAS mutant models. This expansion allows for more detailed insights into mutation-driven cancers. 🔍 Flexible Model Selection: Our platform offers flexible model selection, starting from 20 models. This flexibility ensures that you can design your own panel tailored to your specific research needs. OrganoidXplore™ continues to be the first large panel-based organoid screening service, unique to Crown Bioscience. It accelerates drug discovery and development, from lead compound identification to selecting the right models and indications for meaningful results. Join us on this journey to revolutionize drug discovery and development! #DrugDiscovery #CancerResearch #Organoids #KRAS #Biotech #Innovation #CrownBioscience

Don't get stuck trying to use a nuclease that 'gets close' to where you want to edit in the genome because there is not a PAM sequence close by - close is not good enough. Use a nuclease that provides you the flexibility you need to edit your desired gene target. One of the many benefits of Synthego Corporation's hfCas12Max is its broad PAM sequence recognition profile, which enables gene editing in locations previously deemed uneditable using current nuclease options. Casey Jowdy does a great, easy-to-follow walkthrough about hfCas12Max and its abilities in a variety of gene editing applications. #CRISPR